Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE: ctDNA-guided adjuvant FOLFOX6m in stage II colon cancer
2019-000935-15Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jun 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin in colon cancer (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: 3-year disease-free survival (DFS). Started Jun 2019; status: active.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2019-000935-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000935-15.